Lysicamine
Based on 1 Customer Validation
Lysicamine, a natural compound, possesses antibacterial, anticancer and anti-inflammation activity.
For research use only. We do not sell to patients.
- Purity : 99.34%
- CAS No.: 15444-20-9
- Formula: C18H13NO3
- Molecular Weight:291.30
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
>40 μM
Compound: 4K
|
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 35092899] |
| HepG2 | IC50 |
6.2 μg/mL
Compound: 7
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 11374955] |
| HepG2 2.2.15 | IC50 |
2.4 μg/mL
Compound: 7
|
Cytotoxicity against human HepG2(2.2.15) cells by MTT assay
Cytotoxicity against human HepG2(2.2.15) cells by MTT assay
|
[PMID: 11374955] |
| KB | ED50 |
>10 μg/mL
Compound: lysicamine
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
10.1021/np50019a011 |
| MGC-803 | IC50 |
15.8 μM
Compound: 4K
|
Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 35092899] |
| RAW264.7 | IC50 |
6.4 μM
Compound: 9
|
Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay
Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay
|
[PMID: 33939429] |
| SK-OV-3 | IC50 |
12.1 μM
Compound: 4K
|
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 35092899] |
| T-24 | IC50 |
7.3 μM
Compound: 4K
|
Antiproliferative activity against human T24 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human T24 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 35092899] |
| Vero | CC50 |
500 μM
Compound: 17
|
Cytotoxicity against african green monkey Vero cells
Cytotoxicity against african green monkey Vero cells
|
[PMID: 9584402] |
| WI-38 | IC50 |
6.7 μM
Compound: 4K
|
Antiproliferative activity against human WI-38 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human WI-38 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 35092899] |
Chemical Information
-
CAS No. 15444-20-9
-
Appearance Solid
-
Molecular Weight 291.30
-
Formula C18H13NO3
-
Color Light yellow to yellow
-
SMILES
O=C1C2=CC=CC=C2C3=C(OC)C(OC)=CC4=CC=NC1=C43
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lysicamine Related Classifications
HY-122930 Related Classifications
Powered by Bioz